Skip to content

Natalie Gukasyan

Columbia University Irving Medical Center

31 papers in the library · 1,741 citations · publishing 2021-2026

Papers

Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors.

Int Rev Psychiatry September 11, 2024 Mary E. Yaden, Terence H. W. Ching, Noam Goldway et al. 2 citations

A survey of US psychiatry residency training directors found that most (64%) favor adding more time for psychedelic education, yet many worry about a lack of educational materials (54%) and limited faculty to teach the content (46%). Almost all programs (94%) expressed some interest in a standardized curriculum in psychedelic medicine. Training directors recognize current offerings are limited and want more support to meet the coming demand for education in this emerging field.

DOI: 10.1080/09540261.2024.2397039 Psychedelic-assisted therapy Psychedelic therapies Innovative treatments Promising new modalities +11

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

Psychiatry Research February 13, 2026 Sean P. Goldy, Nathan D. Sepeda, Samantha Hilbert et al. 1 citation

The acute subjective effects of psychedelics are known to predict therapeutic benefits like reduced depression and anxiety. Session facilitators—who support participants before, during, and after dosing—are a key part of the setting, but their influence on subjective effects was unclear. Analyzing data from 9 psilocybin studies with 298 participants, 670 sessions, and 60 facilitators, multilevel models showed facilitators accounted for negligible variance (0.8%) in healthy volunteers but greater variance in clinical samples (13.6%), after controlling for study and participant differences. This suggests facilitators may play a clinically meaningful role in shaping outcomes for patient populations, comparable to or exceeding therapist effects in traditional psychotherapy (~8%).

DOI: 10.1016/j.psychres.2026.117010 Psilocybin Session web analytics Clinical trial Multilevel model +12

Serotonergic antidepressant use is associated with weaker psilocybin effects

October 28, 2022 Natalie Gukasyan, Roland R. Griffiths, David B. Yaden et al. 1 citation preprint

Serotonergic antidepressants, such as SSRIs and SNRIs, weaken psilocybin's effects, while the non-serotonergic antidepressant bupropion has less of a dampening effect. In 595 reports of taking psilocybin with an antidepressant, the probability of weaker than expected effects was 0.48 for SSRIs, 0.56 for SNRIs, and 0.29 for bupropion. After discontinuing a serotonergic antidepressant, reduced psilocybin effects persisted for up to 3 months, with odds of reduced effects not significantly different from the first week until 3–6 months post-discontinuation. The findings suggest that serotonergic antidepressants diminish psilocybin's effects both concurrently and for months after stopping.

DOI: 10.31234/osf.io/2zys9 Full text Psilocybin Serotonergic Serotonin Antidepressant +6

Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care.

Current psychiatry reports May 14, 2026 Jamarie A Geller, Rachel Pacilio, Amanda E Downey et al.

Psilocybin-assisted therapy may hold promise for anorexia nervosa, a serious and often treatment-resistant illness. Although research has focused on adults, anorexia frequently begins in adolescence, and early onset is linked to more severe illness, greater psychiatric comorbidity, and more life difficulties. The authors argue that exploring the theoretical potential of this therapy for adolescents is warranted, considering biological implications, developmental stage, and consent. They propose adaptations to adult treatment models and discuss emerging models that address the unique challenges of adolescent patients.

DOI: 10.1007/s11920-026-01679-z Full text Psilocybin Psychedelic therapy Adolescent psychiatry Anorexia nervosa